NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) assays utilizing a sugar-engineered anti CD70 antibody with a nonfucosylated Fc backbone (SEA-CD70) were performed against AML cell lines with varying CD70 expression levels and primary AML cells (n=6)...However, these pro-inflammatory stimuli inhibit NK-mediated ADCC activity. This data warrant future studies to understand how modulation of the TME may be utilized as a strategy to enhance target expression without negatively impacting effector cell functions.

2 years ago

Clinical • IO biomarker

IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD33 (CD33 Molecule) • CD70 (CD70 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)

CD70 expression • CD33 expression

PF-08046040

4years

[VIRTUAL] A Phase 1 Study of Sea-CD70 in Myeloid Malignancies (ASH 2020)

Methods SGNS70-101 is a phase 1, open-label, multicenter, dose-escalation, and cohort expansion study designed to establish the safety, tolerability, and preliminary activity of SEA-CD70 in pts with myeloid malignancies (NCT04227847). Once dose escalation is complete and the recommended monotherapy dose is identified, combination cohorts will be considered in AML and MDS. The study is currently enrolling with sites opening in the US and EU.

4 years ago

P1 data • IO biomarker

CD70 (CD70 Molecule) • CD27 (CD27 Molecule)

CD70 expression

PF-08046040 • vorsetuzumab (SGN70)